Verified
LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
Chi, K. N. N., Castro, E., Attard, G., Smith, M. R., Sandhu, S. K., Efstathiou, E., Roubaud, G., Small, E. J. J., Gomes, A. J. P. D. S., Rathkopf, D., et al. (2023) · Annals of Oncology
Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy
Cited by 12
